I don't know what is typical for a risk % for go-to market in this industry. It seems 35% is very conservative as per Euroz language. As all we can do is speculate, so:
10% risk = $1.423m valuation ($1 per share)
x 3 for US population (assuming 3x patients and similar uptake/sales)
= $4.269m valuation ($3 per share)
Pie in the sky, perhaps. But even somewhere in the middle I'd be more than happy based on SB alone, as long as we can get the other products closer to fruition to increase takeover value per share.
Having said that, in Sep we could be offered a good chunk by BP and that is the end of the journey. Not long now..
Ann: Investor Webinar Presentation, page-34
-
- There are more pages in this discussion • 36 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.5¢ |
Change
0.020(6.15%) |
Mkt cap ! $624.4M | |||
| Open | High | Low | Value | Volume |
| 32.5¢ | 34.5¢ | 32.5¢ | $2.676M | 7.955M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 19000 | 34.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.5¢ | 48210 | 1 |
View Market Depth
| Last trade - 16.10pm 03/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |